An important recent development is that research now shows that individuals with mild cognitive impairment are at a very high risk of developing Alzheimer's disease. A number of ongoing clinical trials are recruiting such individuals to test whether certain drugs are effective in reducing the rate at which they progress to Alzheimer's disease. It is expected that future clinical trials will focus increasingly on early intervention.

DRUGS AND THERAPIES
We list all drugs (four to date) approved by the FDA for treatment of Alzheimer's, as well as medications available over the counter or for other indications which may target disease mechanisms that are thought to be important in Alzheimer's. We also list nutriceuticals (nutritional supplements not regulated by the FDA), alternative therapies and nonpharmacologic interventions. Each listed therapy is linked to a datasheet that provides details on research studies, citations and documented efficacy.


DRUGS IN CLINICAL TRIALS
Some two dozen compounds are currently in clinical trials, and more are coming into the pipeline every year. We track all compounds that have reached Phase II (that is, they have passed Phase I safety trials). Although by definition these are not yet proved to be effective, they offer added possibilities for treatment.